{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:29:29Z","timestamp":1776997769075,"version":"3.51.4"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Pre-exposure prophylaxis (PrEP) is an important tool for preventing HIV infection. However, PrEP\u2019s impact on cardiometabolic health is understudied.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the risk of incident hypertension and statin initiation among adult (age \u226518 years) health plan members starting PrEP with tenofovir alafenamide fumarate (TAF) compared with propensity score\u2013matched adults taking tenofovir disoproxil fumarate (TDF).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study used electronic health records (EHRs) from Kaiser Permanente Southern California. Adult members starting PrEP in Kaiser Permanente Southern California between October 2019 and May 2022 were included. Propensity score matching with multiple imputation (50 matched data sets) was conducted to generate 1 TAF:4 TDF matched data sets with balanced baseline covariates.<\/jats:p><\/jats:sec>Exposures<\/jats:title>PrEP initiation with either TAF or TDF during the study period.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Incident hypertension and statin initiation within 2 years of PrEP initiation were ascertained through blood pressure and outpatient pharmacy records, respectively. Risk differences and odds ratios (ORs) were estimated using logistic regression and g-computation.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 6824 eligible individuals were identified (mean [SD] age, 33.9 [10.3] years; 6618 [97%] male). This pool was used to generate 2 cohorts without baseline hypertension or statin use for matching (hypertension: n\u2009=\u20095523; statin: n\u2009=\u20096149) In both cohorts, those starting PrEP with TAF were older and were more likely to be non-Hispanic White compared with those starting with TDF. In matched analysis adjusting for baseline covariates, TAF use was associated with elevated risk of incident hypertension (TAF: n\u2009=\u2009371; risk difference, 0.81 [95% CI, 0.12-1.50]; OR, 1.64 [95% CI, 1.05-2.56]). TAF use was also associated with elevated risk of statin initiation (TAF: n\u2009=\u2009382; risk difference, 0.85 [95% CI, 0.37-1.33]; OR, 2.33 [95% CI, 1.41-3.85]). Subgroup analyses restricted to individuals 40 years and older at PrEP initiation showed similar results with larger risk difference in statin initiation (risk difference, 4.24 [95% CI, 1.82-6.26]; OR, 3.05 [95% CI, 1.64-5.67]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study of people taking PrEP, TAF use was found to be associated with higher incident hypertension and statin initiation compared with TDF use, especially in those 40 years or older. Continued monitoring of blood pressure and lipids for TAF users is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.32968","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:01:14Z","timestamp":1694444474000},"page":"e2332968","source":"Crossref","is-referenced-by-count":20,"title":["Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins"],"prefix":"10.1001","volume":"6","author":[{"given":"Adovich S.","family":"Rivera","sequence":"first","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine J.","family":"Pak","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Mefford","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rulin C.","family":"Hechter","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"},{"name":"Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"issue":"9","key":"zoi230953r1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States.","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"issue":"22","key":"zoi230953r2","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.2019.6390","article-title":"Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement.","volume":"321","author":"Owens","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"zoi230953r4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(20)30497-7","article-title":"Cabotegravir, a new option for PrEP.","volume":"20","author":"Kirby","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"zoi230953r5","doi-asserted-by":"publisher","DOI":"10.1177\/2325958220919231","article-title":"A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide.","author":"Wassner","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4","key":"zoi230953r6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2055-6640(20)30312-5","article-title":"How safe is TDF\/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP.","volume":"4","author":"Pilkington","year":"2018","journal-title":"J Virus Erad"},{"issue":"10246","key":"zoi230953r7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"zoi230953r8","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"8","author":"Ogbuagu","year":"2021","journal-title":"Lancet HIV"},{"issue":"4","key":"zoi230953r9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bcpt.2019.124.issue-4","article-title":"Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.","volume":"124","author":"Cid-Silva","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"S1","key":"zoi230953r10","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1097\/QAI.0000000000003040","article-title":"Higher risk of dyslipidemia with coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide than efavirenz, lamivudine, and tenofovir disoproxil fumarate among antiretroviral-naive people living with HIV in China.","volume":"91","author":"Sun","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"zoi230953r11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1089\/apc.2019.0236","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting.","volume":"33","author":"Kauppinen","year":"2019","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"zoi230953r12","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.v24.4","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study.","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"zoi230953r13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV.","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi230953r14","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"zoi230953r15","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life\u2019s essential 8: updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: a presidential advisory from the American Heart Association.","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"issue":"8","key":"zoi230953r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.22692","article-title":"Characterization of HIV preexposure prophylaxis use behaviors and HIV incidence among US adults in an integrated health care system.","volume":"4","author":"Hojilla","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230953r19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ajh.2011.179","article-title":"Underdiagnosis of hypertension using electronic health records.","volume":"25","author":"Banerjee","year":"2012","journal-title":"Am J Hypertens"},{"issue":"16","key":"zoi230953r20","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials.","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"},{"key":"zoi230953r21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"zoi230953r22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7812\/TPP\/12-031","article-title":"Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.","volume":"16","author":"Koebnick","year":"2012","journal-title":"Perm J"},{"issue":"2","key":"zoi230953r23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7812\/TPP\/22.172","article-title":"Comparing Kaiser Permanente members to the general population: implications for generalizability of research.","volume":"27","author":"Davis","year":"2023","journal-title":"Perm J"},{"issue":"7","key":"zoi230953r24","first-page":"503","article-title":"JNC8 guidelines for the management of hypertension in adults.","volume":"90","author":"Armstrong","year":"2014","journal-title":"Am Fam Physician"},{"issue":"11","key":"zoi230953r25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1161\/CIRCULATIONAHA.121.054602","article-title":"Harmonization of the American College of Cardiology\/American Heart Association and European Society of Cardiology\/European Society of Hypertension blood pressure\/hypertension guidelines: comparisons, reflections, and recommendations.","volume":"146","author":"Whelton","year":"2022","journal-title":"Circulation"},{"key":"zoi230953r26","doi-asserted-by":"publisher","DOI":"10.1177\/1178222616685880","article-title":"Using electronic medical record to identify patients with dyslipidemia in primary care settings: international classification of disease code matters from one region to a national database.","author":"Oake","journal-title":"Biomed Inform Insights"},{"issue":"11","key":"zoi230953r27","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1161\/HYPERTENSIONAHA.122.19302","article-title":"Association of cumulative viral load with the incidence of hypertension and diabetes in people With HIV.","volume":"79","author":"Rivera","year":"2022","journal-title":"Hypertension"},{"issue":"9","key":"zoi230953r28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/aje\/kwq224","article-title":"Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score.","volume":"172","author":"Austin","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"1","key":"zoi230953r29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/epirev\/mxab003","article-title":"Matching methods for confounder adjustment: an addition to the epidemiologist\u2019s toolbox.","volume":"43","author":"Greifer","year":"2022","journal-title":"Epidemiol Rev"},{"issue":"3","key":"zoi230953r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"mice: Multivariate imputation by chained equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"issue":"8","key":"zoi230953r31","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference.","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"issue":"1","key":"zoi230953r34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40121-020-00384-5","article-title":"Patient-focused selection of PrEP medication for individuals at risk of HIV: a narrative review.","volume":"10","author":"Fields","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"6","key":"zoi230953r35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"issue":"3","key":"zoi230953r36","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study.","volume":"76","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi230953r37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cid\/ciy083","article-title":"Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine.","volume":"67","author":"Glidden","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"14","key":"zoi230953r38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"zoi230953r39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios.","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"issue":"7","key":"zoi230953r40","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.18502\/ijph.v50i7.6626","article-title":"Evaluation of multiple imputation with large proportions of missing data: how much is too much?","volume":"50","author":"Lee","year":"2021","journal-title":"Iran J Public Health"},{"issue":"2","key":"zoi230953r41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/bimj.v57.2","article-title":"Performance of the marginal structural models under various scenarios of incomplete marker\u2019s values: a simulation study.","volume":"57","author":"Vourli","year":"2015","journal-title":"Biom J"},{"issue":"7","key":"zoi230953r42","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/aje\/kws213","article-title":"Invited commentary: structural equation models and epidemiologic analysis.","volume":"176","author":"VanderWeele","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi230953r43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1089\/apc.2021.0033","article-title":"Why Are patients switching from tenofovir disoproxil fumarate\/emtricitabine (Truvada) to tenofovir alafenamide\/emtricitabine (Descovy) for pre-exposure prophylaxis?","volume":"35","author":"D\u2019Angelo","year":"2021","journal-title":"AIDS Patient Care STDS"},{"key":"zoi230953r3","unstructured":"Global AIDS strategy 2021-2026. UNAIDS. Accessed August 8, 2023. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/global-AIDS-strategy-2021-2026_en.pdf"},{"key":"zoi230953r16","unstructured":"Mounzer? K, Clarke? A, Doblecki-Lewis? S, . Lipid parameters and lipid-modifying agent use in participants initiating F\/TAF or F\/TDF for PrEP in the DISCOVER Trial. Presented at: 24th International AIDS Conference; 2022; Montreal, Canada. Accessed May 18, 2023. https:\/\/www.natap.org\/2022\/IAC\/IAC_17.htm"},{"key":"zoi230953r18","unstructured":"Yap? AG. Metabolic adverse effects of different HIV pre-exposure prophylaxis medications in minority populations: a United States multicenter research network propensity-matched analysis. University of Texas at Austin; 2022. Accessed August 8, 2023. https:\/\/repositories.lib.utexas.edu\/handle\/2152\/117151"},{"key":"zoi230953r32","doi-asserted-by":"crossref","unstructured":"Pishgar? F, Greifer? N, Leyrat? C, Stuart? E. MatchThem: matching and weighting after multiple imputation.? arXiv. Preprint posted online September 24, 2020. doi:10.48550\/arXiv.2009.11772","DOI":"10.32614\/RJ-2021-073"},{"key":"zoi230953r33","unstructured":"Arel-Bundock? V. marginaleffects 0.13.0. Accessed August 8, 2023. https:\/\/vincentarelbundock.github.io\/marginaleffects\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809151\/rivera_2023_oi_230953_1693416397.49296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:01:21Z","timestamp":1694444481000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.32968","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]}}}